Is There a Future for AKT Inhibitors in the Treatment of Cancer?

被引：36
|
作者：
Jansen, Valerie M. [1 ]
Mayer, Ingrid A. [1 ]
Arteaga, Carlos L. [1 ]
机构：
[1] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Breast Canc Program, Nashville, TN 37232 USA
来源：
CLINICAL CANCER RESEARCH | 2016年 / 22卷 / 11期
关键词：
METASTATIC BREAST-CANCER; COMBINATION; THERAPY; DOMAIN;
D O I：
10.1158/1078-0432.CCR-16-0100
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
An AKT inhibitor plus an antiestrogen exhibited no significant clinical activity in patients with ER+/HER2(-) breast cancer despite laboratory studies supporting an antitumor effect for both drugs combined. These results raise concerns about the development of AKT inhibitors in unselected patients whose tumors have unknown dependence on the PI3K/AKT pathway. (C) 2016 AACR.
引用
收藏
页码：2599 / 2601
页数：3
相关论文
共 50 条
  • [1] Is There a Future for AKT Inhibitors in the Treatment of Cancer? (vol 22, pg 2599, 2016)
    Jansen, Valerie M.
    Mayer, Ingrid A.
    Arteaga, Carlos L.
    CLINICAL CANCER RESEARCH, 2019, 25 (04) : 1436 - 1436
  • [2] Akt inhibitors in clinical development for the treatment of cancer
    Pal, Sumanta Kumar
    Reckamp, Karen
    Yu, Hua
    Figlin, Robert A.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (11) : 1355 - 1366
  • [3] Discovery and development of allosteric AKT inhibitors for the treatment of cancer
    Sanderson, Philip E.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 241
  • [4] Cancer treatment of the future: Inhibitors of histone methyltransferases
    Spannhoff, Astrid
    Sippl, Wolfgang
    Jung, Manfred
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2009, 41 (01): : 4 - 11
  • [5] Azole-based inhibitors of AKT/PKB for the treatment of cancer
    Zeng, Qingping
    Allen, John G.
    Bourbeau, Matthew P.
    Wang, Xianghong
    Yao, Guomin
    Tadesse, Seifu
    Rider, James T.
    Yuan, Chester C.
    Hong, Fang-Tsao
    Lee, Matthew R.
    Zhang, Shiwen
    Lofgren, Julie A.
    Freeman, Daniel J.
    Yang, Suijin
    Li, Chun
    Tominey, Elizabeth
    Huang, Xin
    Hoffman, Douglas
    Yamane, Harvey K.
    Fotsch, Christopher
    Dominguez, Celia
    Hungate, Randall
    Zhang, Xiaoling
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (05) : 1559 - 1564
  • [6] Discovery of oral allosteric AKT kinase inhibitors for the treatment of cancer
    Layton, Mark
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 246
  • [7] Endogenous proteinase inhibitors as future targets in the treatment of cancer
    Schroll, A. S.
    Lademann, U.
    Christensen, I. J.
    Foekens, J.
    Nielsen, H. J.
    Wuertz, S.
    Davidsen, L.
    Bruenner, N.
    FEBS JOURNAL, 2006, 273 : 28 - 28
  • [8] Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors
    Feng, Shu
    Shao, Longjiang
    Castro, Patricia
    Coleman, Ilsa
    Nelson, Peter S.
    Smith, Paul D.
    Davies, Barry R.
    Ittmann, Michael
    ONCOTARGET, 2017, 8 (04) : 6179 - 6192
  • [9] Future perspectives for mTOR inhibitors in renal cell cancer treatment
    Czarnecka, Anna M.
    Kornakiewicz, Anna
    Lian, Fei
    Szczylik, Cezary
    FUTURE ONCOLOGY, 2015, 11 (05) : 801 - 817
  • [10] FKBP5 as a Selection Biomarker for Gemcitabine and Akt Inhibitors in Treatment of Pancreatic Cancer
    Hou, Junmei
    Wang, Liewei
    PLOS ONE, 2012, 7 (05):
12345